MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Rigel Pharmaceuticals Operating Income 2011-2026 | RIGL
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Rigel Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.2 M | -20.5 M | -55.6 M | -12.5 M | -29 M | -69.1 M | -72.7 M | -79.6 M | -69.7 M | -51.7 M | -91.2 M | -89.5 M | -99.4 M | -86.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.2 M | -99.4 M | -57.3 M |
Quarterly Operating Income Rigel Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.4 M | 61.1 M | 12.8 M | 14.1 M | 447 K | -6.97 M | -4.46 M | -5.27 M | -12.7 M | - | -18.4 M | -13 M | -26.3 M | - | -19.8 M | -13 M | 41.8 M | - | -13.8 M | -17.4 M | 21 M | - | -12 M | -21.3 M | -18.4 M | - | -24.4 M | -26.1 M | -24.7 M | - | -17.9 M | -19.3 M | -16.2 M | - | -22.7 M | -13.6 M | -17.6 M | - | -6.78 M | -14 M | -18.2 M | - | -21 M | -25.5 M | -22.4 M | - | -23.9 M | -22.9 M | -25.7 M | - | -25.6 M | -24.9 M | -23.3 M | - | -18 M | -21.6 M | -20.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 61.1 M | -26.3 M | -11.6 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
55.4 M | $ 20.15 | -2.68 % | $ 2.54 B |  USA |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Axsome Therapeutics
AXSM
|
-167 M | $ 163.7 | -1.61 % | $ 8.14 B | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 3.72 | -2.75 % | $ 1.11 B |  Canada |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
242 M | $ 8.52 | -2.46 % | $ 1.39 B | Britain |
 |
Corvus Pharmaceuticals
CRVS
|
-23.4 M | $ 17.75 | -0.79 % | $ 852 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Certara
CERT
|
21 M | $ 7.16 | 1.49 % | $ 1.15 B | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
-24.1 M | $ 25.91 | -3.56 % | $ 694 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
-58.5 M | $ 0.99 | -3.28 % | $ 72.7 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
258 M | $ 24.0 | 0.5 % | $ 2.93 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-160 M | $ 3.19 | -4.64 % | $ 1.14 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-472 M | $ 28.78 | -1.44 % | $ 1.67 B | USA |
 |
Champions Oncology
CSBR
|
4.55 M | $ 6.0 | -1.15 % | $ 82 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
-131 M | $ 3.67 | -3.42 % | $ 116 M | France |
 |
Alector
ALEC
|
-156 M | $ 2.11 | -4.75 % | $ 217 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-188 M | $ 15.68 | -2.4 % | $ 779 M | Britain |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
-103 M | $ 4.17 | 0.24 % | $ 296 M | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
-50.2 M | $ 14.27 | 2.44 % | $ 5.92 B |  Irlanda |